NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
key details
| Value | £198,666,666 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 +2 more |
| Deadline | 16 Mar 2022 |
| Procedure | open |
| OCID | ocds-h6vhtk-0314ad |
Awards (10)
This procurement was awarded to 10 suppliers. Values shown are per-award; the notice total is £198,666,666.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Accord-UK Ltd shared | · | · | active |
| BioCryst Ireland Limited shared | · | · | active |
| Celix Pharma Ltd. shared | · | · | active |
| Cipla shared | · | · | active |
| CSL Behring UK Ltd shared | · | · | active |
| Martindale Pharma shared | · | · | active |
| Pharming Group shared | · | · | active |
| Piramal Critical care Limited shared | · | · | active |
| Takeda UK Ltd shared | · | · | active |
| Wockhardt UK Limited shared | · | · | active |
description
National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
notice history
5 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 8 Feb 2022 | Contract notice (F02) | Earlier regulations | 003602-2022 |
| 5 Jul 2022 | Planning (planning) | · | b493c8a8-51ee-4005-aa56-ae479ec70ab7-552190 |
| 19 Jul 2022 | Contract award notice (F03) | Earlier regulations | 019699-2022 |
| 21 Jul 2022 | Corrigendum (F14) | Earlier regulations | 019862-2022 |
| 15 Aug 2023 | Planning (planning) | · | 61761bed-b882-4318-9253-bf33fd8ad367-671962 |
more from NHS England
- Urgent Award - haematological screening · £16,202 · 29 Jul 2026
- HSCN-AWS Connectivity Service for Spine · £228,060 · 29 Jul 2026
- Incentive Voucher Provider · £60,000 · 29 Jul 2026
- CRM for NHSE participant/candidate data 26-27 · £56,640 · 28 Jul 2026
- Wayfinder and First Contact Digital Clinical Support 2026-27 · £748,000 · 23 Jul 2026
- Support Services for PPM application · £860,000 · 22 Jul 2026
- Digital Maturity Assessment · 21 Jul 2026
- Integrated Healthcare Services to Haslar Immigration Removal Centre (IRC) · £19,052,186 · 13 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.